175358-02-8

Basic information

• Product Name: 4,6-Dichloropyrido[3,2-d]pyrimidine
• Synonyms: 4,6-Dichloropyrido[3,2-d]pyrimidine
• CAS NO: 175358-02-8
• Molecular Formula: C₇H₃Cl₂N₃
• Molecular Weight: 200.028
• Mol File: 175358-02-8.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 314.616 °C at 760 mmHg
• Flash Point: 173.301 °C
• Appearance: /
• Density: 1.573
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.682
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.89±0.30(Predicted)
• CAS DataBase Reference: 4,6-Dichloropyrido[3,2-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-Dichloropyrido[3,2-d]pyrimidine(175358-02-8)
• EPA Substance Registry System: 4,6-Dichloropyrido[3,2-d]pyrimidine(175358-02-8)

Safety Data

• Hazardous Substances Data: 175358-02-8(Hazardous Substances Data)

Usage

General Description

4,6-Dichloropyrido[3,2-d]pyrimidine is a chemical compound with the molecular formula C7H3Cl2N3. It belongs to the class of organic compounds known as pyrido[3,2-d]pyrimidines, which are polycyclic aromatic compounds containing a pyrido[3,2-d]pyrimidine moiety, which consists of a pyridine ring fused to a pyrimidine ring. It's less commonly utilized and not as widely studied, thus its potential applications are still largely unknown. Acquiring an understanding of its reactivity and chemical interactions could vastly contribute to its potential uses in various chemical-based industries.

InChI:InChI=1/C7H3Cl2N3/c8-5-2-1-4-6(12-5)7(9)11-3-10-4/h1-3H

Upstream product

• 866807-27-4 3-amino-6-chloro-pyridine-2-carboxylic acid 
• 37538-67-3 pyrido[3,2-d]-pyrimidin-4(3H)-one 
• 2402-78-0 2,6-dichloropyridine 
• 16013-85-7 2,6-dicholoro-3-nitropyridine 
• 1242446-83-8 4-chloropyrido[3,2-d]pyrimidin-6-ol 
• 171178-33-9 6-chloropyrido[3,2-d]pyrimidin-4(1H)-one 
• 171178-21-5 6-chloro-3-nitropyridine-2-carboxamide 
• 175358-01-7 3-amino-6-chloro-pyridine-2-carboxylic acid amide 
• 93683-65-9 6-chloro-3-nitropicolinonitrile 
• 171178-33-9 6-chloropyrido<3,2-d>pyrimidin-4(3H)-one 

Downstream Products

• 855995-88-9 {2-[(allyl-methyl-amino)-methyl]-5-chloro-4-fluoro-phenyl}-(6-chloro-pyrido [3,2-d] pyrimidin-4-yl)-amine 
• 1242446-26-9 6-chloro-4-(3-(trifluoromethyl)phenyl)pyrido[3,2-d]pyrimidine 
• 1400668-23-6 6-chloro-N-(4-(trifluoromethoxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine 
• 1400668-15-6 6-chloro-4-(cyclohexylthio)pyrido[3,2-d]pyrimidine 

Relevant articles and documents

ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT

The present invention concerns a compound of following general formula (I): where: either R is an R1 group and R′ is an -A1-Cy1 group, or R is an -A1-Cy1 group and R′ is an R1 group, R1 particularly being H or (C1-C6)alkyl group;A1 being an —NH— radical or —NH—CH2— radical;Cy1 particularly being a phenyl group,A is a fused (hetero)aromatic ring having 5 to 7 atoms, for use for treating cancer.

Optimization of 4,6-Disubstituted Pyrido[3,2-d]pyrimidines as Dual MNK/PIM Inhibitors to Inhibit Leukemia Cell Growth

Mitogen-activated protein kinase-interacting kinases (MNKs) and provirus integration in maloney murine leukemia virus kinases (PIMs) are downstream enzymes of cell proliferation signaling pathways associated with the resistance of tyrosine kinase inhibitors. MNKs and PIMs have complementary effects to regulate cap-dependent translation of oncoproteins. Dual inhibitors of MNKs and PIMs have not been developed. We developed a novel 4,6-disubstituted pyrido[3,2-d]pyrimidine compound 21o with selective inhibition of MNKs and PIMs. The IC50’s of 21o to inhibit MNK1 and MNK2 are 1 and 7 nM and those to inhibit PIM1, PIM2, and PIM3 are 43, 232, and 774 nM, respectively. 21o inhibits the growth of myeloid leukemia K562 and MOLM-13 cells with GI50’s of 2.1 and 1.2 μM, respectively. 21o decreases the levels ofp-eIF4E andp-4EBP1, the downstream products of MNKs and PIMs, as well as cap-dependent proteins c-myc, cyclin D1, and Mcl-1. 21o inhibits the growth of MOLM-13 cell xenografts without causing evident toxicity. 21o represents an innovative dual MNK/PIM inhibitor with a good pharmacokinetic profile.

HETEROCYCLIC INHIBITORS OF TYROSINE KINASE

The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of HER2 or EGFR for the treatment or prevention of disease, including cancer.